On February 7, 2025, Nevro Corp was acquired by Globus ... that was initially anticipated based on clinical trial outcomes. The U.S. SCS market remains highly competitive, with larger companies ...

Nevro Corp. NVRO reported ... by ongoing softness in the U.S. SCS market and competitive pressures. Total U.S. permanent implant procedures, as well as U.S. trial procedures, declined in the ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European ... as well as U.S. trial ...

U.S. permanent implant procedures decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial ... treatment. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform ...

Headquartered in Redwood City, California, Nevro is known for its Senza® spinal cord stimulation (SCS) system, which utilizes HF10® therapy to provide relief from chronic pain. The company ...

U.S. permanent implant procedures decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial procedures ... Nevro's comprehensive HFX spinal cord stimulation (SCS) platform ...

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased ... powers the HFX iQ spinal cord stimulation (SCS) system. In addition to the U.S. market ...